X4 Pharmaceuticals(XFOR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway; submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET ...